Prescient Therapeutics provides PTX-100 trial update, readies for investor briefing
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Since the last trial update, a patient with relapsed peripheral T cell lymphoma reported a...
Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published...
It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings...
Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical...
Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the...
Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously...
Prescient Therapeutics Ltd (ASX:PTX) continues to demonstrate a favourable safety profile with its PTX-100 Phase 1b expansion...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
“It is very exciting to see PTX-100 show clinical activity in a patient population that...
A study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.